NCT01453322

Brief Summary

The objective of this study is to confirm and document that with the use of a FDA Class I exempt near infrared device, VeinViewer® Vision that is hands-free and can be used for healthy adult volunteers with varying skin types to assist in the improved visualization, it is possible to film, analyze and document PIV localized complications and venous flow and refill.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 12, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 17, 2011

Completed
Last Updated

October 18, 2011

Status Verified

October 1, 2011

Enrollment Period

Same day

First QC Date

October 12, 2011

Last Update Submit

October 17, 2011

Conditions

Keywords

VeinsVascular AccessIV complicationsVeinViewer Vision

Outcome Measures

Primary Outcomes (1)

  • Valve and Refill Confirmation

    Using VeinViewer, the clinician will be able to view valves and refill. It will be confirmed using Ultrasound.

    Immediately after flush-Day 1

Secondary Outcomes (1)

  • Video Documentation of localized vascular access complications

    Immediately after attempt-Day 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy adult volunteers

You may qualify if:

  • Must be 18 years of age or older
  • Must be considered in good health by investigator
  • Must be able to read and understand English

You may not qualify if:

  • Less than 18 years of age
  • Known allergy to Heparin
  • History of HIT (Heparin-induced thrombocytopenia)
  • Unable to read and understand English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Key Biologics LLC

Memphis, Tennessee, 38104, United States

Location

Study Officials

  • Edward P Scott, MD

    Key Biologics, LLC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 12, 2011

First Posted

October 17, 2011

Study Start

September 1, 2011

Primary Completion

September 1, 2011

Study Completion

September 1, 2011

Last Updated

October 18, 2011

Record last verified: 2011-10

Locations